| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium Infections | 91 | 2024 | 231 | 26.540 |
Why?
|
| Anti-Bacterial Agents | 90 | 2025 | 2397 | 9.730 |
Why?
|
| Vancomycin | 24 | 2025 | 217 | 5.730 |
Why?
|
| Cross Infection | 24 | 2022 | 332 | 5.610 |
Why?
|
| Antifungal Agents | 22 | 2023 | 293 | 4.600 |
Why?
|
| Ribotyping | 22 | 2024 | 45 | 4.270 |
Why?
|
| Candidemia | 12 | 2023 | 40 | 3.970 |
Why?
|
| Microbial Sensitivity Tests | 46 | 2024 | 798 | 3.950 |
Why?
|
| Candida | 14 | 2023 | 75 | 3.920 |
Why?
|
| Bacterial Toxins | 24 | 2024 | 176 | 3.830 |
Why?
|
| Enterocolitis, Pseudomembranous | 21 | 2022 | 93 | 3.810 |
Why?
|
| Diarrhea | 21 | 2023 | 315 | 3.240 |
Why?
|
| Anti-Infective Agents | 13 | 2024 | 266 | 2.820 |
Why?
|
| Pharmacy Service, Hospital | 9 | 2018 | 49 | 2.790 |
Why?
|
| Pseudomonas aeruginosa | 12 | 2012 | 164 | 2.780 |
Why?
|
| Gastrointestinal Microbiome | 11 | 2024 | 680 | 2.750 |
Why?
|
| Echinocandins | 9 | 2023 | 44 | 2.690 |
Why?
|
| Feces | 23 | 2025 | 710 | 2.670 |
Why?
|
| Pharmacists | 10 | 2020 | 83 | 2.580 |
Why?
|
| Candidiasis | 12 | 2022 | 129 | 2.540 |
Why?
|
| Antimicrobial Stewardship | 5 | 2020 | 84 | 2.370 |
Why?
|
| Bacteremia | 12 | 2019 | 406 | 2.370 |
Why?
|
| Gram-Positive Bacteria | 5 | 2019 | 46 | 2.320 |
Why?
|
| Drug Resistance, Bacterial | 14 | 2024 | 362 | 2.220 |
Why?
|
| Humans | 227 | 2025 | 123181 | 2.160 |
Why?
|
| Fluconazole | 8 | 2012 | 47 | 2.130 |
Why?
|
| Bacterial Proteins | 19 | 2024 | 876 | 2.090 |
Why?
|
| Bacteria | 8 | 2022 | 483 | 2.020 |
Why?
|
| Rifamycins | 8 | 2013 | 21 | 1.960 |
Why?
|
| Bile Acids and Salts | 4 | 2025 | 234 | 1.880 |
Why?
|
| Environmental Microbiology | 5 | 2019 | 16 | 1.800 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2025 | 227 | 1.730 |
Why?
|
| Bacterial Infections | 7 | 2018 | 305 | 1.640 |
Why?
|
| Gram-Positive Bacterial Infections | 4 | 2018 | 75 | 1.610 |
Why?
|
| Medication Errors | 4 | 2019 | 184 | 1.610 |
Why?
|
| Middle Aged | 77 | 2025 | 25976 | 1.590 |
Why?
|
| Patient Discharge | 4 | 2022 | 488 | 1.580 |
Why?
|
| Tetracyclines | 5 | 2025 | 14 | 1.530 |
Why?
|
| Aged | 68 | 2024 | 19068 | 1.490 |
Why?
|
| Metronidazole | 10 | 2024 | 155 | 1.480 |
Why?
|
| Pseudomonas Infections | 5 | 2010 | 114 | 1.440 |
Why?
|
| Blood Culture | 3 | 2019 | 29 | 1.420 |
Why?
|
| Antibiotic Prophylaxis | 5 | 2011 | 117 | 1.390 |
Why?
|
| Health Care Costs | 6 | 2019 | 365 | 1.360 |
Why?
|
| Male | 99 | 2025 | 60018 | 1.310 |
Why?
|
| Ceftriaxone | 2 | 2020 | 68 | 1.270 |
Why?
|
| Spores, Bacterial | 6 | 2022 | 21 | 1.260 |
Why?
|
| Candidiasis, Invasive | 2 | 2022 | 19 | 1.260 |
Why?
|
| Adult | 63 | 2025 | 29035 | 1.260 |
Why?
|
| Female | 99 | 2025 | 65426 | 1.250 |
Why?
|
| Microbiota | 3 | 2023 | 392 | 1.250 |
Why?
|
| Candida glabrata | 5 | 2018 | 18 | 1.210 |
Why?
|
| Texas | 28 | 2021 | 3548 | 1.200 |
Why?
|
| Carbapenems | 4 | 2020 | 36 | 1.190 |
Why?
|
| Proanthocyanidins | 3 | 2013 | 6 | 1.180 |
Why?
|
| Antidiarrheals | 3 | 2013 | 17 | 1.180 |
Why?
|
| Aged, 80 and over | 29 | 2024 | 6371 | 1.160 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 5 | 2018 | 149 | 1.140 |
Why?
|
| Lipopeptides | 7 | 2023 | 33 | 1.130 |
Why?
|
| Community-Acquired Infections | 4 | 2022 | 241 | 1.100 |
Why?
|
| Length of Stay | 13 | 2019 | 1284 | 1.040 |
Why?
|
| Vitamin D Deficiency | 2 | 2021 | 70 | 1.030 |
Why?
|
| Hospitals | 8 | 2021 | 397 | 1.030 |
Why?
|
| Community Pharmacy Services | 3 | 2020 | 10 | 1.020 |
Why?
|
| Dog Diseases | 3 | 2022 | 49 | 0.990 |
Why?
|
| Fatty Acids, Volatile | 1 | 2025 | 33 | 0.970 |
Why?
|
| Enterotoxins | 11 | 2023 | 82 | 0.960 |
Why?
|
| Students, Pharmacy | 5 | 2020 | 63 | 0.960 |
Why?
|
| Fecal Microbiota Transplantation | 3 | 2023 | 93 | 0.960 |
Why?
|
| Benchmarking | 2 | 2016 | 132 | 0.950 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2024 | 114 | 0.930 |
Why?
|
| Faculty | 3 | 2014 | 100 | 0.920 |
Why?
|
| Purine Nucleosides | 1 | 2024 | 6 | 0.920 |
Why?
|
| beta-Lactamases | 4 | 2011 | 195 | 0.890 |
Why?
|
| Education, Pharmacy | 5 | 2020 | 54 | 0.890 |
Why?
|
| Proton Pump Inhibitors | 2 | 2024 | 254 | 0.870 |
Why?
|
| Hospitalization | 9 | 2021 | 1733 | 0.870 |
Why?
|
| Neutrophils | 2 | 2024 | 372 | 0.860 |
Why?
|
| Disinfection | 4 | 2019 | 25 | 0.860 |
Why?
|
| Fluoroquinolones | 5 | 2023 | 99 | 0.850 |
Why?
|
| Hospitals, University | 8 | 2014 | 96 | 0.840 |
Why?
|
| Severity of Illness Index | 7 | 2017 | 2838 | 0.820 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2020 | 220 | 0.820 |
Why?
|
| Actinobacteria | 1 | 2022 | 13 | 0.820 |
Why?
|
| Prospective Studies | 23 | 2023 | 6028 | 0.810 |
Why?
|
| Recurrence | 11 | 2023 | 1420 | 0.810 |
Why?
|
| Protease Inhibitors | 2 | 2021 | 95 | 0.790 |
Why?
|
| Medical Order Entry Systems | 3 | 2019 | 98 | 0.790 |
Why?
|
| Equipment Contamination | 2 | 2019 | 38 | 0.790 |
Why?
|
| Schools, Pharmacy | 5 | 2020 | 22 | 0.770 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2018 | 288 | 0.770 |
Why?
|
| Biofilms | 4 | 2020 | 93 | 0.760 |
Why?
|
| Risk Factors | 26 | 2023 | 10001 | 0.750 |
Why?
|
| Pharmacy Residencies | 3 | 2020 | 5 | 0.750 |
Why?
|
| Surgical Wound Infection | 4 | 2007 | 260 | 0.750 |
Why?
|
| Lopinavir | 1 | 2021 | 7 | 0.740 |
Why?
|
| Macrophages | 1 | 2024 | 607 | 0.730 |
Why?
|
| Acinetobacter baumannii | 2 | 2011 | 36 | 0.730 |
Why?
|
| Pharmacy | 1 | 2020 | 13 | 0.720 |
Why?
|
| Ritonavir | 1 | 2021 | 54 | 0.710 |
Why?
|
| Prevalence | 11 | 2023 | 2405 | 0.710 |
Why?
|
| Pharmaceutical Services | 5 | 2020 | 35 | 0.710 |
Why?
|
| Floors and Floorcoverings | 2 | 2017 | 3 | 0.710 |
Why?
|
| Molecular Epidemiology | 5 | 2021 | 156 | 0.690 |
Why?
|
| Amphotericin B | 4 | 2012 | 90 | 0.690 |
Why?
|
| Shoes | 2 | 2017 | 24 | 0.680 |
Why?
|
| beta-Lactam Resistance | 3 | 2011 | 47 | 0.670 |
Why?
|
| Animals, Zoo | 1 | 2019 | 15 | 0.660 |
Why?
|
| Vancomycin Resistance | 5 | 2024 | 20 | 0.650 |
Why?
|
| Retrospective Studies | 26 | 2023 | 15979 | 0.650 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 499 | 0.640 |
Why?
|
| Program Development | 2 | 2020 | 190 | 0.640 |
Why?
|
| Chromatography, Liquid | 3 | 2025 | 191 | 0.640 |
Why?
|
| Intensive Care Units | 5 | 2014 | 484 | 0.640 |
Why?
|
| Clarithromycin | 3 | 2008 | 124 | 0.630 |
Why?
|
| Healthy Volunteers | 3 | 2025 | 131 | 0.630 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 46 | 0.630 |
Why?
|
| Multivariate Analysis | 9 | 2019 | 1418 | 0.630 |
Why?
|
| Respiratory Tract Infections | 2 | 2017 | 263 | 0.620 |
Why?
|
| Polymerase Chain Reaction | 9 | 2020 | 1586 | 0.620 |
Why?
|
| Rifampin | 2 | 2010 | 146 | 0.620 |
Why?
|
| Drug Compounding | 1 | 2018 | 34 | 0.620 |
Why?
|
| Cohort Studies | 17 | 2024 | 4708 | 0.600 |
Why?
|
| Drug Resistance, Fungal | 3 | 2014 | 25 | 0.600 |
Why?
|
| Peritonitis | 1 | 2018 | 76 | 0.590 |
Why?
|
| Communicable Diseases | 5 | 2021 | 163 | 0.590 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 305 | 0.590 |
Why?
|
| Surveys and Questionnaires | 9 | 2023 | 3662 | 0.590 |
Why?
|
| Neoplasms | 5 | 2023 | 2767 | 0.580 |
Why?
|
| Urban Population | 3 | 2019 | 221 | 0.570 |
Why?
|
| Staphylococcus aureus | 3 | 2012 | 457 | 0.570 |
Why?
|
| Coronary Artery Bypass | 4 | 2008 | 485 | 0.560 |
Why?
|
| Quality of Life | 5 | 2023 | 1931 | 0.560 |
Why?
|
| Fungal Proteins | 2 | 2015 | 134 | 0.560 |
Why?
|
| Ultraviolet Rays | 1 | 2017 | 204 | 0.550 |
Why?
|
| Drug Prescriptions | 2 | 2015 | 216 | 0.550 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 170 | 0.550 |
Why?
|
| Decontamination | 1 | 2016 | 12 | 0.550 |
Why?
|
| Disease Transmission, Infectious | 2 | 2019 | 86 | 0.550 |
Why?
|
| Robotics | 1 | 2018 | 106 | 0.550 |
Why?
|
| Surface Properties | 1 | 2016 | 76 | 0.550 |
Why?
|
| Treatment Outcome | 21 | 2024 | 12102 | 0.540 |
Why?
|
| Interleukin-8 | 5 | 2017 | 208 | 0.530 |
Why?
|
| Genotype | 2 | 2021 | 2548 | 0.520 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2014 | 711 | 0.520 |
Why?
|
| Bifidobacterium | 3 | 2021 | 63 | 0.510 |
Why?
|
| Pyridines | 6 | 2024 | 222 | 0.510 |
Why?
|
| Health Facilities | 1 | 2016 | 59 | 0.510 |
Why?
|
| Voriconazole | 1 | 2015 | 35 | 0.500 |
Why?
|
| Infection Control | 3 | 2017 | 160 | 0.490 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2015 | 56 | 0.490 |
Why?
|
| Fungemia | 4 | 2007 | 22 | 0.490 |
Why?
|
| ADP Ribose Transferases | 3 | 2020 | 18 | 0.490 |
Why?
|
| Benzimidazoles | 5 | 2024 | 128 | 0.480 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 321 | 0.480 |
Why?
|
| Health Care Surveys | 2 | 2016 | 284 | 0.470 |
Why?
|
| Drug Interactions | 8 | 2019 | 254 | 0.470 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 97 | 0.460 |
Why?
|
| Mentors | 1 | 2016 | 145 | 0.460 |
Why?
|
| Liver Diseases | 1 | 2018 | 362 | 0.460 |
Why?
|
| Escherichia coli | 3 | 2022 | 980 | 0.440 |
Why?
|
| Creatinine | 3 | 2013 | 380 | 0.440 |
Why?
|
| HIV Infections | 3 | 2021 | 1868 | 0.440 |
Why?
|
| Family Characteristics | 1 | 2014 | 78 | 0.440 |
Why?
|
| Leadership | 1 | 2016 | 227 | 0.440 |
Why?
|
| Pilot Projects | 7 | 2021 | 1387 | 0.430 |
Why?
|
| Catheter-Related Infections | 2 | 2012 | 131 | 0.430 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2006 | 1102 | 0.430 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2024 | 2599 | 0.430 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2024 | 333 | 0.430 |
Why?
|
| Patient Readmission | 2 | 2016 | 365 | 0.420 |
Why?
|
| Piperacillin | 3 | 2010 | 13 | 0.420 |
Why?
|
| Medication Therapy Management | 1 | 2012 | 25 | 0.410 |
Why?
|
| Daptomycin | 1 | 2012 | 13 | 0.410 |
Why?
|
| Time Factors | 11 | 2021 | 6201 | 0.410 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2024 | 515 | 0.410 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 850 | 0.410 |
Why?
|
| Electronic Health Records | 1 | 2019 | 698 | 0.400 |
Why?
|
| Esomeprazole | 1 | 2012 | 31 | 0.400 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 1069 | 0.390 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2012 | 45 | 0.390 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 1684 | 0.390 |
Why?
|
| Sunlight | 1 | 2011 | 23 | 0.390 |
Why?
|
| Ambulatory Care | 1 | 2015 | 376 | 0.390 |
Why?
|
| Gastrointestinal Diseases | 3 | 2010 | 335 | 0.380 |
Why?
|
| Young Adult | 12 | 2025 | 8868 | 0.380 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 481 | 0.380 |
Why?
|
| Enterococcus | 2 | 2014 | 32 | 0.380 |
Why?
|
| Fomites | 1 | 2011 | 5 | 0.380 |
Why?
|
| Prognosis | 7 | 2021 | 4508 | 0.380 |
Why?
|
| Sensitivity and Specificity | 7 | 2024 | 2024 | 0.380 |
Why?
|
| Odds Ratio | 6 | 2018 | 1245 | 0.370 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1013 | 0.370 |
Why?
|
| Mutation | 5 | 2024 | 5777 | 0.370 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 1314 | 0.370 |
Why?
|
| Helicobacter Infections | 1 | 2021 | 1256 | 0.370 |
Why?
|
| Acinetobacter Infections | 1 | 2011 | 26 | 0.370 |
Why?
|
| Medication Adherence | 1 | 2015 | 388 | 0.370 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 116 | 0.360 |
Why?
|
| Staphylococcal Infections | 3 | 2019 | 553 | 0.360 |
Why?
|
| Intestinal Secretions | 1 | 2010 | 4 | 0.350 |
Why?
|
| Gastrointestinal Tract | 2 | 2023 | 208 | 0.350 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 2851 | 0.350 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 233 | 0.350 |
Why?
|
| Anticoagulants | 1 | 2015 | 585 | 0.350 |
Why?
|
| Bacterial Adhesion | 2 | 2020 | 108 | 0.340 |
Why?
|
| Clinical Trials as Topic | 9 | 2019 | 1088 | 0.340 |
Why?
|
| Patients | 1 | 2011 | 121 | 0.340 |
Why?
|
| Vitamin D | 1 | 2011 | 159 | 0.340 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 225 | 0.340 |
Why?
|
| Animals | 16 | 2024 | 33732 | 0.340 |
Why?
|
| Logistic Models | 6 | 2016 | 1799 | 0.340 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2010 | 62 | 0.340 |
Why?
|
| Public Health Surveillance | 2 | 2019 | 37 | 0.340 |
Why?
|
| Methicillin Resistance | 2 | 2007 | 117 | 0.330 |
Why?
|
| Incidence | 5 | 2019 | 3050 | 0.330 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 1338 | 0.330 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2021 | 265 | 0.320 |
Why?
|
| Drug Utilization | 4 | 2020 | 158 | 0.320 |
Why?
|
| Microbiological Techniques | 2 | 2019 | 33 | 0.320 |
Why?
|
| Cell Wall | 2 | 2021 | 34 | 0.320 |
Why?
|
| Administration, Oral | 5 | 2020 | 671 | 0.320 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1677 | 0.320 |
Why?
|
| Azithromycin | 2 | 1999 | 45 | 0.320 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2015 | 597 | 0.320 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2008 | 425 | 0.310 |
Why?
|
| Delivery of Health Care | 4 | 2021 | 606 | 0.310 |
Why?
|
| Toxemia | 2 | 2020 | 3 | 0.310 |
Why?
|
| Cefuroxime | 1 | 2007 | 15 | 0.300 |
Why?
|
| Colony Count, Microbial | 3 | 2019 | 89 | 0.300 |
Why?
|
| Hospitals, Community | 2 | 2020 | 55 | 0.300 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 401 | 0.290 |
Why?
|
| United States | 8 | 2023 | 10618 | 0.290 |
Why?
|
| Treatment Failure | 3 | 2021 | 338 | 0.290 |
Why?
|
| Aminoglycosides | 4 | 2017 | 45 | 0.290 |
Why?
|
| Outpatients | 2 | 2022 | 254 | 0.280 |
Why?
|
| Tertiary Care Centers | 3 | 2018 | 236 | 0.280 |
Why?
|
| Case-Control Studies | 5 | 2018 | 3260 | 0.280 |
Why?
|
| Immunization Programs | 2 | 2007 | 63 | 0.280 |
Why?
|
| Hospital Costs | 2 | 2019 | 178 | 0.280 |
Why?
|
| Canada | 2 | 2023 | 294 | 0.280 |
Why?
|
| Academic Medical Centers | 4 | 2020 | 298 | 0.270 |
Why?
|
| Sternum | 1 | 2006 | 53 | 0.270 |
Why?
|
| Blood | 2 | 2018 | 105 | 0.270 |
Why?
|
| Health Personnel | 1 | 2011 | 500 | 0.260 |
Why?
|
| Breath Tests | 2 | 2004 | 179 | 0.260 |
Why?
|
| Disinfectants | 2 | 2019 | 25 | 0.260 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2018 | 118 | 0.260 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 86 | 0.260 |
Why?
|
| Double-Blind Method | 3 | 2024 | 1588 | 0.250 |
Why?
|
| Drug Therapy, Combination | 5 | 2011 | 1149 | 0.250 |
Why?
|
| Body Mass Index | 1 | 2011 | 1543 | 0.250 |
Why?
|
| Dysbiosis | 2 | 2024 | 120 | 0.250 |
Why?
|
| Macrolides | 2 | 2003 | 28 | 0.250 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 3377 | 0.250 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2025 | 14 | 0.240 |
Why?
|
| Genes, Bacterial | 2 | 2019 | 208 | 0.240 |
Why?
|
| Telephone | 2 | 2015 | 109 | 0.240 |
Why?
|
| Asthma | 3 | 2003 | 746 | 0.240 |
Why?
|
| Hospital Mortality | 3 | 2021 | 1004 | 0.230 |
Why?
|
| Dogs | 3 | 2022 | 763 | 0.230 |
Why?
|
| Phagocytosis | 1 | 2024 | 170 | 0.230 |
Why?
|
| General Surgery | 1 | 2006 | 203 | 0.230 |
Why?
|
| Critical Illness | 2 | 2022 | 595 | 0.230 |
Why?
|
| Adolescent | 12 | 2023 | 19086 | 0.220 |
Why?
|
| Nonprescription Drugs | 1 | 2004 | 46 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2008 | 443 | 0.220 |
Why?
|
| Pharmaceutical Preparations | 1 | 2004 | 80 | 0.220 |
Why?
|
| Toxoids | 1 | 2023 | 7 | 0.210 |
Why?
|
| Fusobacteria | 1 | 2022 | 1 | 0.210 |
Why?
|
| Microscopy | 1 | 2024 | 118 | 0.210 |
Why?
|
| Certification | 1 | 2003 | 68 | 0.210 |
Why?
|
| Freeze Drying | 1 | 2022 | 14 | 0.210 |
Why?
|
| Fusobacterium Infections | 1 | 2022 | 14 | 0.210 |
Why?
|
| Nitroimidazoles | 1 | 2023 | 51 | 0.210 |
Why?
|
| Microbial Viability | 3 | 2017 | 41 | 0.210 |
Why?
|
| Bangladesh | 2 | 2019 | 20 | 0.210 |
Why?
|
| Renal Dialysis | 2 | 2006 | 842 | 0.210 |
Why?
|
| Carrier State | 2 | 2021 | 76 | 0.200 |
Why?
|
| Virulence | 2 | 2020 | 259 | 0.200 |
Why?
|
| Attitude of Health Personnel | 3 | 2020 | 640 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2019 | 256 | 0.200 |
Why?
|
| Rhinitis | 1 | 2003 | 38 | 0.200 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 234 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 825 | 0.200 |
Why?
|
| Vaccination | 2 | 2007 | 949 | 0.200 |
Why?
|
| Interleukin-1beta | 1 | 2023 | 160 | 0.200 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2022 | 80 | 0.200 |
Why?
|
| Drug Resistance, Microbial | 3 | 2011 | 193 | 0.200 |
Why?
|
| Peptides, Cyclic | 3 | 2017 | 53 | 0.200 |
Why?
|
| Cytokines | 5 | 2021 | 1284 | 0.200 |
Why?
|
| Models, Psychological | 2 | 2020 | 139 | 0.200 |
Why?
|
| Program Evaluation | 3 | 2020 | 449 | 0.200 |
Why?
|
| Ketolides | 1 | 2001 | 4 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2001 | 280 | 0.190 |
Why?
|
| Binding Sites | 1 | 2024 | 1292 | 0.190 |
Why?
|
| Cunninghamella | 1 | 2001 | 3 | 0.190 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 481 | 0.190 |
Why?
|
| Virginiamycin | 1 | 2001 | 3 | 0.190 |
Why?
|
| Thailand | 2 | 2011 | 34 | 0.190 |
Why?
|
| Mammals | 1 | 2023 | 262 | 0.190 |
Why?
|
| Bronchiolitis | 1 | 2003 | 119 | 0.190 |
Why?
|
| Sinusitis | 1 | 2003 | 117 | 0.190 |
Why?
|
| Lung Diseases, Fungal | 1 | 2001 | 33 | 0.190 |
Why?
|
| Mucormycosis | 1 | 2001 | 26 | 0.190 |
Why?
|
| Enterococcus faecalis | 1 | 2001 | 43 | 0.190 |
Why?
|
| Decision Making | 1 | 2006 | 649 | 0.180 |
Why?
|
| Gram-Negative Bacteria | 2 | 2016 | 67 | 0.180 |
Why?
|
| Pharmacies | 1 | 2020 | 13 | 0.180 |
Why?
|
| Fusobacterium nucleatum | 1 | 2020 | 24 | 0.180 |
Why?
|
| Chloride Channels | 2 | 2012 | 62 | 0.180 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 286 | 0.180 |
Why?
|
| Serologic Tests | 2 | 2018 | 119 | 0.180 |
Why?
|
| Adhesins, Bacterial | 1 | 2020 | 75 | 0.180 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 774 | 0.180 |
Why?
|
| Absenteeism | 1 | 2020 | 19 | 0.180 |
Why?
|
| Zebrafish | 1 | 2023 | 384 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 152 | 0.170 |
Why?
|
| Oxazolidinones | 2 | 2017 | 36 | 0.170 |
Why?
|
| Travel | 2 | 2012 | 117 | 0.170 |
Why?
|
| Prednisone | 1 | 2000 | 273 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3098 | 0.170 |
Why?
|
| Encephalitis | 1 | 2001 | 108 | 0.170 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 126 | 0.170 |
Why?
|
| Bacterial Typing Techniques | 1 | 2020 | 103 | 0.170 |
Why?
|
| Preceptorship | 1 | 2020 | 33 | 0.170 |
Why?
|
| Staphylococcus epidermidis | 1 | 2019 | 41 | 0.170 |
Why?
|
| Enteritis | 1 | 2020 | 54 | 0.170 |
Why?
|
| Jejunum | 1 | 2020 | 128 | 0.170 |
Why?
|
| Tosyl Compounds | 1 | 1999 | 21 | 0.170 |
Why?
|
| Glucose | 2 | 2021 | 869 | 0.160 |
Why?
|
| Leukotriene Antagonists | 1 | 1999 | 17 | 0.160 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 1999 | 3 | 0.160 |
Why?
|
| Serotonin | 1 | 2020 | 222 | 0.160 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2019 | 24 | 0.160 |
Why?
|
| Naphthyridines | 1 | 1999 | 6 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 42 | 0.160 |
Why?
|
| Child | 11 | 2023 | 24208 | 0.160 |
Why?
|
| Immunoglobulin G | 4 | 2023 | 771 | 0.160 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 481 | 0.160 |
Why?
|
| Smoking | 2 | 2004 | 1032 | 0.160 |
Why?
|
| Bacteriological Techniques | 1 | 2019 | 91 | 0.160 |
Why?
|
| Teaching | 1 | 2020 | 182 | 0.160 |
Why?
|
| Minority Groups | 1 | 2020 | 250 | 0.160 |
Why?
|
| Cost Savings | 1 | 2019 | 69 | 0.160 |
Why?
|
| Hospitals, Teaching | 2 | 2009 | 104 | 0.160 |
Why?
|
| Risk | 2 | 2014 | 750 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 576 | 0.150 |
Why?
|
| Glucosyltransferases | 3 | 2017 | 44 | 0.150 |
Why?
|
| Public Health | 1 | 2020 | 261 | 0.150 |
Why?
|
| Clinical Audit | 1 | 2018 | 5 | 0.150 |
Why?
|
| Azathioprine | 1 | 1998 | 54 | 0.150 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 48 | 0.150 |
Why?
|
| Propensity Score | 1 | 2019 | 206 | 0.150 |
Why?
|
| Phylogeny | 3 | 2021 | 685 | 0.150 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 379 | 0.150 |
Why?
|
| Chronic Disease | 2 | 2018 | 1167 | 0.150 |
Why?
|
| Pneumonia, Bacterial | 1 | 1999 | 77 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2000 | 379 | 0.150 |
Why?
|
| Societies, Pharmaceutical | 2 | 2015 | 11 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2019 | 103 | 0.150 |
Why?
|
| Barbiturates | 1 | 1997 | 7 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 1259 | 0.150 |
Why?
|
| Imipramine | 1 | 1997 | 18 | 0.150 |
Why?
|
| Medication Systems, Hospital | 1 | 2017 | 42 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 730 | 0.150 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1997 | 26 | 0.150 |
Why?
|
| Calcium Signaling | 1 | 2019 | 241 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2015 | 1070 | 0.140 |
Why?
|
| Drug Hypersensitivity | 1 | 1998 | 96 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1211 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2019 | 1169 | 0.140 |
Why?
|
| Medical Oncology | 1 | 2018 | 213 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2020 | 1114 | 0.130 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 2017 | 152 | 0.130 |
Why?
|
| Mucin-2 | 3 | 2020 | 40 | 0.130 |
Why?
|
| Autophagy | 1 | 2019 | 390 | 0.130 |
Why?
|
| Mucositis | 1 | 2015 | 18 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 280 | 0.130 |
Why?
|
| Tertiary Healthcare | 1 | 2015 | 21 | 0.130 |
Why?
|
| Genome, Bacterial | 3 | 2021 | 184 | 0.130 |
Why?
|
| Health Literacy | 1 | 2016 | 79 | 0.130 |
Why?
|
| Optical Imaging | 1 | 2016 | 66 | 0.130 |
Why?
|
| Triose-Phosphate Isomerase | 1 | 2015 | 5 | 0.130 |
Why?
|
| Health Resources | 1 | 2016 | 116 | 0.130 |
Why?
|
| beta-Glucans | 1 | 2015 | 20 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 208 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 29 | 0.120 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2022 | 91 | 0.120 |
Why?
|
| In Vitro Techniques | 2 | 2019 | 966 | 0.120 |
Why?
|
| International Normalized Ratio | 1 | 2015 | 42 | 0.120 |
Why?
|
| Biomass | 2 | 2019 | 17 | 0.120 |
Why?
|
| Costs and Cost Analysis | 2 | 2007 | 164 | 0.120 |
Why?
|
| Electronic Mail | 1 | 2015 | 40 | 0.120 |
Why?
|
| Nanospheres | 1 | 2014 | 6 | 0.120 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2014 | 9 | 0.120 |
Why?
|
| Global Health | 1 | 2019 | 557 | 0.120 |
Why?
|
| Meningitis | 1 | 2015 | 99 | 0.120 |
Why?
|
| Automation | 2 | 2017 | 59 | 0.120 |
Why?
|
| Glutamine | 1 | 2015 | 195 | 0.120 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 151 | 0.120 |
Why?
|
| Thiazoles | 2 | 2017 | 97 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2015 | 148 | 0.120 |
Why?
|
| Thromboembolism | 1 | 2015 | 84 | 0.120 |
Why?
|
| Data Collection | 2 | 2014 | 386 | 0.120 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 92 | 0.120 |
Why?
|
| Biomarkers | 3 | 2021 | 2943 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 645 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 5047 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 3 | 2023 | 262 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2020 | 3332 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 156 | 0.110 |
Why?
|
| Bronchodilator Agents | 1 | 2015 | 153 | 0.110 |
Why?
|
| Disease Outbreaks | 2 | 2018 | 320 | 0.110 |
Why?
|
| Specialization | 1 | 2014 | 76 | 0.110 |
Why?
|
| Secondary Prevention | 2 | 2012 | 211 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 94 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 149 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2014 | 63 | 0.110 |
Why?
|
| Genomics | 1 | 2021 | 1477 | 0.110 |
Why?
|
| Rats | 1 | 2020 | 3631 | 0.110 |
Why?
|
| Organizational Policy | 1 | 2013 | 51 | 0.110 |
Why?
|
| United Kingdom | 2 | 2010 | 195 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1015 | 0.100 |
Why?
|
| Serum | 1 | 2013 | 46 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 773 | 0.100 |
Why?
|
| Biological Therapy | 1 | 2012 | 20 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1404 | 0.100 |
Why?
|
| Models, Organizational | 1 | 2012 | 40 | 0.100 |
Why?
|
| Thienamycins | 1 | 2012 | 15 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2015 | 374 | 0.100 |
Why?
|
| Creatine Kinase | 1 | 2012 | 54 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2024 | 4508 | 0.100 |
Why?
|
| Heme | 2 | 2023 | 53 | 0.100 |
Why?
|
| Drug Evaluation | 1 | 2012 | 111 | 0.100 |
Why?
|
| Fosfomycin | 1 | 2011 | 2 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 819 | 0.100 |
Why?
|
| Imipenem | 1 | 2011 | 9 | 0.100 |
Why?
|
| Child, Preschool | 6 | 2023 | 13862 | 0.100 |
Why?
|
| APACHE | 1 | 2011 | 52 | 0.100 |
Why?
|
| Alcohols | 1 | 2011 | 16 | 0.090 |
Why?
|
| Colistin | 1 | 2011 | 30 | 0.090 |
Why?
|
| Immunoglobulin A | 2 | 2023 | 197 | 0.090 |
Why?
|
| Colon | 1 | 2014 | 353 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 158 | 0.090 |
Why?
|
| Placebos | 1 | 2011 | 238 | 0.090 |
Why?
|
| Brazil | 2 | 2022 | 121 | 0.090 |
Why?
|
| Nitro Compounds | 1 | 2010 | 18 | 0.090 |
Why?
|
| Ireland | 1 | 2010 | 27 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 68 | 0.090 |
Why?
|
| Cell Line | 1 | 2015 | 2779 | 0.090 |
Why?
|
| Professional Practice | 1 | 2010 | 42 | 0.090 |
Why?
|
| Germ-Free Life | 2 | 2020 | 59 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 209 | 0.080 |
Why?
|
| Hepatic Encephalopathy | 1 | 2010 | 74 | 0.080 |
Why?
|
| Agar | 2 | 2021 | 16 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 571 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 254 | 0.080 |
Why?
|
| Colorimetry | 1 | 2008 | 16 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 715 | 0.080 |
Why?
|
| Blotting, Southern | 1 | 2008 | 214 | 0.080 |
Why?
|
| Critical Care | 1 | 2014 | 650 | 0.080 |
Why?
|
| Publications | 1 | 2008 | 33 | 0.080 |
Why?
|
| Peer Review | 1 | 2008 | 41 | 0.080 |
Why?
|
| Societies | 2 | 2018 | 26 | 0.080 |
Why?
|
| Mice | 4 | 2020 | 17492 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 264 | 0.080 |
Why?
|
| Penicillanic Acid | 1 | 2008 | 9 | 0.080 |
Why?
|
| Linear Models | 2 | 2008 | 671 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2006 | 313 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2010 | 357 | 0.080 |
Why?
|
| Coagulase | 1 | 2007 | 22 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2012 | 547 | 0.070 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2010 | 206 | 0.070 |
Why?
|
| Vero Cells | 2 | 2020 | 111 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 321 | 0.070 |
Why?
|
| Staphylococcus | 1 | 2007 | 69 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2011 | 1470 | 0.070 |
Why?
|
| Organoids | 2 | 2020 | 276 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 43 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 1005 | 0.070 |
Why?
|
| Isoelectric Focusing | 1 | 2007 | 24 | 0.070 |
Why?
|
| Antibodies, Bacterial | 2 | 2022 | 382 | 0.070 |
Why?
|
| Spectrophotometry | 1 | 2007 | 58 | 0.070 |
Why?
|
| DNA Fingerprinting | 1 | 2007 | 108 | 0.070 |
Why?
|
| Dysentery | 1 | 2006 | 4 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 313 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 810 | 0.070 |
Why?
|
| Hospitals, General | 1 | 2006 | 24 | 0.070 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2007 | 107 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1011 | 0.070 |
Why?
|
| Hospital Departments | 1 | 2006 | 15 | 0.070 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2006 | 114 | 0.070 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 300 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2007 | 401 | 0.070 |
Why?
|
| Physicians | 1 | 2012 | 584 | 0.070 |
Why?
|
| Caco-2 Cells | 2 | 2016 | 96 | 0.070 |
Why?
|
| Point Mutation | 1 | 2007 | 348 | 0.060 |
Why?
|
| Cations, Divalent | 1 | 2005 | 19 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 1102 | 0.060 |
Why?
|
| ROC Curve | 1 | 2006 | 557 | 0.060 |
Why?
|
| Curriculum | 2 | 2020 | 722 | 0.060 |
Why?
|
| Refuse Disposal | 1 | 2004 | 5 | 0.060 |
Why?
|
| Survivors | 1 | 2007 | 345 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1760 | 0.060 |
Why?
|
| Oxadiazoles | 1 | 2024 | 25 | 0.060 |
Why?
|
| Intestinal Absorption | 1 | 2005 | 190 | 0.060 |
Why?
|
| Enteral Nutrition | 1 | 2006 | 250 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1294 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 1569 | 0.060 |
Why?
|
| Nitrites | 1 | 2004 | 41 | 0.060 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2004 | 61 | 0.060 |
Why?
|
| Heart Failure | 1 | 2016 | 2125 | 0.060 |
Why?
|
| Phosphatidylglycerols | 1 | 2003 | 5 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2004 | 141 | 0.050 |
Why?
|
| Deoxycholic Acid | 1 | 2003 | 13 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2021 | 278 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2003 | 78 | 0.050 |
Why?
|
| Phosphatidylcholines | 1 | 2003 | 41 | 0.050 |
Why?
|
| Antitoxins | 1 | 2023 | 8 | 0.050 |
Why?
|
| Anaerobiosis | 1 | 2022 | 12 | 0.050 |
Why?
|
| Body Weight | 1 | 2007 | 999 | 0.050 |
Why?
|
| Bronchitis | 1 | 2003 | 34 | 0.050 |
Why?
|
| Nasal Polyps | 1 | 2003 | 24 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2006 | 385 | 0.050 |
Why?
|
| Phenotype | 3 | 2020 | 4225 | 0.050 |
Why?
|
| Vitreous Body | 1 | 2003 | 105 | 0.050 |
Why?
|
| Ciprofloxacin | 1 | 2002 | 66 | 0.050 |
Why?
|
| North America | 1 | 2022 | 234 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2007 | 472 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2007 | 1021 | 0.050 |
Why?
|
| Eye Diseases | 1 | 2003 | 113 | 0.050 |
Why?
|
| Metabolome | 1 | 2024 | 294 | 0.050 |
Why?
|
| DNA | 1 | 2007 | 1592 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2001 | 96 | 0.050 |
Why?
|
| Acids | 1 | 2021 | 28 | 0.050 |
Why?
|
| Flagella | 1 | 2020 | 25 | 0.050 |
Why?
|
| Symbiosis | 1 | 2021 | 65 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2020 | 46 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 670 | 0.050 |
Why?
|
| Bioreactors | 1 | 2020 | 38 | 0.050 |
Why?
|
| Enterochromaffin Cells | 1 | 2020 | 10 | 0.050 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2001 | 79 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2020 | 42 | 0.040 |
Why?
|
| Behavior Control | 1 | 2020 | 11 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2020 | 63 | 0.040 |
Why?
|
| Acetates | 1 | 2020 | 71 | 0.040 |
Why?
|
| Operon | 1 | 2020 | 52 | 0.040 |
Why?
|
| o-Phthalaldehyde | 1 | 2019 | 3 | 0.040 |
Why?
|
| Actin Cytoskeleton | 1 | 2020 | 44 | 0.040 |
Why?
|
| Cell Shape | 1 | 2020 | 61 | 0.040 |
Why?
|
| Sodium Hypochlorite | 1 | 2019 | 7 | 0.040 |
Why?
|
| Inpatients | 2 | 2017 | 492 | 0.040 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2019 | 27 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 2003 | 257 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2019 | 35 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 164 | 0.040 |
Why?
|
| Bacteria, Anaerobic | 1 | 1999 | 9 | 0.040 |
Why?
|
| Cost Control | 2 | 2011 | 24 | 0.040 |
Why?
|
| Ofloxacin | 1 | 1999 | 32 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 157 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 372 | 0.040 |
Why?
|
| Levofloxacin | 1 | 1999 | 47 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2001 | 217 | 0.040 |
Why?
|
| Phenylcarbamates | 1 | 1999 | 15 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2019 | 76 | 0.040 |
Why?
|
| Economics, Pharmaceutical | 1 | 1999 | 8 | 0.040 |
Why?
|
| MEDLINE | 1 | 1999 | 20 | 0.040 |
Why?
|
| Mucins | 1 | 2019 | 74 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 287 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2020 | 134 | 0.040 |
Why?
|
| Social Behavior | 1 | 2020 | 207 | 0.040 |
Why?
|
| Multilocus Sequence Typing | 1 | 2018 | 55 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2018 | 30 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 344 | 0.040 |
Why?
|
| Students | 1 | 2020 | 253 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 1313 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2018 | 71 | 0.040 |
Why?
|
| Models, Animal | 1 | 2020 | 465 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2019 | 143 | 0.040 |
Why?
|
| Infectious Disease Medicine | 1 | 2018 | 12 | 0.040 |
Why?
|
| Professional Role | 2 | 2010 | 57 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 808 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2019 | 104 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 1039 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2019 | 172 | 0.040 |
Why?
|
| Indoles | 1 | 1999 | 181 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 1999 | 312 | 0.040 |
Why?
|
| Motivation | 1 | 2020 | 314 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 252 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 469 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2020 | 477 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1999 | 107 | 0.040 |
Why?
|
| Behavior | 1 | 2017 | 75 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 1861 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 533 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2017 | 44 | 0.040 |
Why?
|
| Nurses | 1 | 2017 | 63 | 0.040 |
Why?
|
| Sulfonamides | 1 | 1999 | 259 | 0.040 |
Why?
|
| Attitude | 1 | 2017 | 119 | 0.040 |
Why?
|
| Benzopyrans | 1 | 2017 | 19 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2001 | 478 | 0.040 |
Why?
|
| Depsipeptides | 1 | 2017 | 10 | 0.040 |
Why?
|
| Interleukin-17 | 1 | 2017 | 118 | 0.030 |
Why?
|
| Thiophenes | 1 | 2017 | 60 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2001 | 740 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 57 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 266 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 2001 | 629 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 229 | 0.030 |
Why?
|
| Culture Media | 1 | 2016 | 182 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1105 | 0.030 |
Why?
|
| Pregnancy | 1 | 2008 | 7124 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 393 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 241 | 0.030 |
Why?
|
| Diverticulitis, Colonic | 1 | 2015 | 7 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 90 | 0.030 |
Why?
|
| Louisiana | 1 | 2015 | 135 | 0.030 |
Why?
|
| Blood Preservation | 1 | 2015 | 30 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 587 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 114 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 511 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 59 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2015 | 63 | 0.030 |
Why?
|
| Candida tropicalis | 1 | 2015 | 16 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 167 | 0.030 |
Why?
|
| Multiple Trauma | 1 | 2015 | 63 | 0.030 |
Why?
|
| Biological Assay | 1 | 2015 | 101 | 0.030 |
Why?
|
| Candida albicans | 1 | 2015 | 76 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 1480 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1597 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 1997 | 451 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 680 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 1090 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 354 | 0.030 |
Why?
|
| Infant | 2 | 2023 | 12323 | 0.030 |
Why?
|
| Psychometrics | 1 | 2016 | 667 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2011 | 33 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2011 | 44 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 383 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 900 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 459 | 0.020 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 18 | 0.020 |
Why?
|
| beta-Lactams | 1 | 2010 | 51 | 0.020 |
Why?
|
| Pharmacy Administration | 1 | 2010 | 2 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2010 | 118 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3287 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 239 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 144 | 0.020 |
Why?
|
| Probiotics | 1 | 2010 | 208 | 0.020 |
Why?
|
| Drug Costs | 1 | 2006 | 61 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2011 | 519 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 195 | 0.020 |
Why?
|
| Intestines | 1 | 2009 | 571 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 815 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2007 | 229 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 252 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2007 | 228 | 0.010 |
Why?
|
| Sex Factors | 1 | 2007 | 1257 | 0.010 |
Why?
|
| Blood Bactericidal Activity | 1 | 2002 | 17 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 271 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 696 | 0.010 |
Why?
|
| Retinal Ganglion Cells | 1 | 2003 | 108 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2005 | 441 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2001 | 98 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2001 | 142 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 168 | 0.010 |
Why?
|
| Retinal Diseases | 1 | 2003 | 172 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 2801 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2005 | 483 | 0.010 |
Why?
|
| Forecasting | 1 | 2001 | 355 | 0.010 |
Why?
|
| Neutropenia | 1 | 2001 | 202 | 0.010 |
Why?
|
| Bacteroides | 1 | 1999 | 34 | 0.010 |
Why?
|
| Lipids | 1 | 2001 | 514 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8089 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1225 | 0.010 |
Why?
|